Apitope: Apitope preps Graves' disease drug for phase 2 after positive trial

Apitope has taken a step closer to developing the first new treatment option for thyroid disorder Graves' disease in decades after posting positive results in a first-in-human trial of its ATX-GD-59 antibody.